newsfilter
← Latest News
GlobeNewswire·

Kineta Announces New Research Agreement to Evaluate VISTA Biomarker Expression

KA

SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,